http://rdf.disgenet.org/resource/nanopub/NP1174608.RAk8kdUSpZ4jgxBUTmPBZp-D6N9V-adIvXK7BxrERIB1w
type: Nanopublication
created: 2016-05-13T12:50:38+02:00
rights: http://opendatacommons.org/licenses/odbl/1.0/
rights holder: IBIGroup
subject: SIO_000983
used data: disgenetv3.0rdf
authored by: http://orcid.org/0000-0001-5999-6269
authored by: http://orcid.org/0000-0002-7534-7661
authored by: 0000-0002-9383-528X
authored by: http://orcid.org/0000-0003-0169-8159
authored by: http://orcid.org/0000-0003-1244-7654
created by: http://orcid.org/0000-0003-0169-8159
version: v4.0.0.0

http://rdf.disgenet.org/resource/nanopub/NP1174608.RAk8kdUSpZ4jgxBUTmPBZp-D6N9V-adIvXK7BxrERIB1w130_assertion
type: Assertion
description: [In addition we briefly reviewed epigenetic agents, such as inhibitors of DNA methyltransferases or HDAC (histone deacetylase) targeting oncology, hematology, immunology, and neurologic disease indications, and which are in various phases of study or have been clinically tested and approved by FDA (Food and Drug Administration).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine.
evidence: DisGeNET evidence - LITERATURE
SIO_000772: http://identifiers.org/pubmed/24743128
was generated by: ECO_0000203

befree-2016
imported on: 2016-02-19

DisGeNET evidence - LITERATURE
type: ECO_0000212
comment: Gene-disease associations inferred from text-mining the literature.

disgenetv3.0rdf
version: v4.0.0